Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)
Status:
Recruiting
Trial end date:
2022-01-14
Target enrollment:
Participant gender:
Summary
Abbreviated Title: Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary
Site (CUP) Trial Phase: 2 Clinical Indication: Treatment naïve patients with poor prognosis
carcinoma of unknown primary site Trial Type: Single arm phase 2 Type of control: Not
applicable Route of administration: Intravenous Trial Blinding: Not applicable Treatment
Groups: 1) Pembrolizumab 200 mg IV every 3 weeks for up to 24 months. Total Number of trial
subjects:25 Estimated enrollment period: 24 months Estimated duration of trial: 48 months
Duration of Participation: 24 months